MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Immunotherapy has transformed hepatocellular carcinoma (HCC) treatment.
• Sorafenib is a key first-line therapy for advanced HCC, but acquired resistance limits its effectiveness.
• Predictive biomarkers are crucial for optimizing sorafenib therapy in HCC patients.

Purpose of the Study:

• To investigate the role of microRNA-22 (miR-22) in metabolic reprogramming within HCC.
• To explore miR-22's potential as a predictive biomarker for sorafenib response in HCC.
• To elucidate the miR-22/GLUT1 axis in HCC progression and drug resistance.

Main Methods:

• Quantitative PCR (qPCR) to analyze miR-22 expression in HCC tissues and models.
• Functional assays in HCC cells to assess GLUT1 as a direct miR-22 target.
• Cellular and metabolic assays to evaluate the miR-22/GLUT1 axis's impact on tumor behavior and sorafenib response.
• Analysis of circulating miR-22 in HCC patients and rats undergoing sorafenib treatment.

Main Results:

• MiR-22 was found to be downregulated in HCC, correlating with aggressive tumor features.
• MiR-22 modulates the HIF1A pathway, enhances cellular survival, promotes glycolysis, and increases sorafenib resistance by targeting GLUT1.
• Elevated serum miR-22 levels were associated with sorafenib resistance in both HCC patients and preclinical models.
• GLUT1 inhibition sensitized HCC cells with low miR-22 expression to sorafenib in preclinical studies.

Conclusions:

• Circulating miR-22 shows promise as a predictive biomarker for sorafenib response in HCC.
• Targeting GLUT1, especially in patients with high circulating miR-22, could be a viable therapeutic strategy to combine with sorafenib.